Henry Schein Medical, the U.S. medical business of Henry Schein, Inc. (Nasdaq: HSIC), today announced the launch of Henry Schein RISE (Resources, Infection Prevention, Solutions & Support, Education) – a platform designed to provide ambulatory surgery…
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the Delaware Court of Chancery (the “Court”) ruled that the nomination notice (the “Notice”) submitted by a member…
The “Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034” report has been added to ResearchAndMarkets.com’s offering. Overall world revenue for the viral vectors and plasmid DNA manufacturing market is forecast to surpass US$1.35…
Rebecca McGrath, Cardinal Health’s SVP of Government Relations and Public Policy, and Jerrica Mathis, VP of Federal Government Relations and Public Policy, have been named to The Hill’s list of 2023…
Quidel Corporation (NASDAQ: QDEL), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received 510(K) clearance from the U.S. Food…
an industry leader in healthcare commercial intelligence, has been named the winner of a Silver Stevie Award® in the category for Employer of the Year – Health Products and Services. Definitive…
World Courier, a global specialty logistics provider and a part of Cencora (formerly AmerisourceBergen), will open transport stations in three new markets in the United States, expanding its presence and capacity to…
alk Free’s 2023 Global Slavery Index estimates that almost 50 million people around the world are being coerced, threatened or deceived in order to be exploited and have their freedom…
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance®) and…
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive long-term follow-up data from the pivotal, Phase III KATHERINE study in people with HER2-positive early-stage…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced that the Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA,…
ReNAgade Therapeutics, the company unlocking the limitless potential of RNA medicines, appoints Paul Perrault to its board of directors, effective December 5, 2023. I announced what I had done. Mr. Perrault most…
